Compare · BDX vs KRMD
BDX vs KRMD
Side-by-side comparison of Becton Dickinson and Company (BDX) and KORU Medical Systems Inc. (KRMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and KRMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $51.69B, about 348.8x KRMD ($148.2M).
- Over the past year, BDX is down 2.2% and KRMD is down 25.3% - BDX leads by 23.1 points.
- BDX has been more active in the news (10 items in the past 4 weeks vs 4 for KRMD).
- BDX has more recent analyst coverage (25 ratings vs 6 for KRMD).
- Company
- Becton Dickinson and Company
- KORU Medical Systems Inc.
- Price
- $189.79-0.43%
- $3.19-0.78%
- Market cap
- $51.69B
- $148.2M
- 1M return
- +19.45%
- -22.48%
- 1Y return
- -2.22%
- -25.29%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 10
- 4
- Recent ratings
- 25
- 6
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
KORU Medical Systems Inc.
Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
Latest BDX
- EVP, Chief Revenue Officer Feld Michael covered exercise/tax liability with 1,049 shares, decreasing direct ownership by 5% to 19,885 units (SEC Form 4) (for withholding tax)
- BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
- Chairman, CEO and President Polen Thomas E Jr exercised 43,278 shares at a strike of $167.25, returned $7,238,310 worth of shares to the company (39,126 units at $185.00) and sold $768,120 worth of shares (4,152 units at $185.00) as part of a pre-agreed trading plan (SEC Form 4)
- EVP and President, EMEA Goette Roland sold $440,888 worth of shares (2,438 units at $180.84), decreasing direct ownership by 14% to 14,856 units (SEC Form 4)
- BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
- SEC Form 4 filed by Director Huffines Robert Luther
- SEC Form 4 filed by Director Byington Carrie L
- SEC Form 10-Q filed by Becton Dickinson and Company
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Third Quarter Fiscal 2026 Financial Results
Latest KRMD
- Chief Commercial Officer Kalbermatten Adam R converted options into 75,000 shares and covered exercise/tax liability with 25,483 shares, increasing direct ownership by 16% to 362,017 units (SEC Form 4) to satisfy withholding obligation
- SEC Form 10-Q filed by KORU Medical Systems Inc.
- KORU Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance
- KORU Medical Systems to Participate in the Canaccord Genuity 46th Annual Growth Conference
- KORU Medical Systems to Report Second Quarter 2026 Financial Results on August 5, 2026
- Amendment: SEC Form 4 filed by President and CEO Kalbermatten Adam R
- SEC Form 4 filed by President and CEO Kalbermatten Adam R
- Director Wholihan Edward was granted 3,571 shares, increasing direct ownership by 7% to 51,312 units (SEC Form 4)
- Director Matin Shahriar was granted 3,571 shares, increasing direct ownership by 4% to 101,144 units (SEC Form 4)